NCT00466960View on ClinicalTrials.gov

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2011

Conditions
Brenner TumorFallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPeritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
BIOLOGICAL

sargramostim

Given SC

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunologic technique

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00466960 - Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | Biotech Hunter | Biotech Hunter